HomeATHA • NASDAQ
add
Athira Pharma Inc
$0.30
Makalipas ang Oras ng Trabaho:(0.34%)+0.0010
$0.30
Sarado: Hun 27, 8:00:00 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$0.30
Sakop ng araw
$0.30 - $0.32
Sakop ng taon
$0.22 - $3.67
Market cap
11.63M USD
Average na Volume
939.21K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 9.54M | -65.56% |
Net na kita | -9.14M | 65.28% |
Net profit margin | — | — |
Kita sa bawat share | — | — |
EBITDA | -9.29M | 66.14% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 36.67M | -69.96% |
Kabuuang asset | 43.51M | -67.40% |
Kabuuang sagutin | 6.18M | -76.86% |
Kabuuang equity | 37.33M | — |
Natitirang share | 39.04M | — |
Presyo para makapag-book | 0.32 | — |
Return on assets | -46.61% | — |
Return on capital | -56.42% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2025info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -9.14M | 65.28% |
Cash mula sa mga operasyon | -14.66M | 43.17% |
Cash mula sa pag-invest | -7.35M | -156.37% |
Cash mula sa financing | — | — |
Net change in cash | -22.02M | -72.50% |
Malayang cash flow | -11.35M | 32.75% |
Tungkol
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Itinatag
2011
Headquarters
Website
Mga Empleyado
26
